BioCentury
ARTICLE | Company News

Flag Therapeutics, Duquesne University deal

December 16, 2013 8:00 AM UTC

Flag acquired exclusive, worldwide rights to anti-antiogenic/anti- tubulin compounds and folate-targeted anti-cancer compounds developed at the university. The agreement includes IP and a compound lib...